Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508763 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL2438588 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL21979446 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL495878 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL5930119 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL23092514 | 1.00 | NPC1 (0.44) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL3169175 | 0.88 | SLC7A5 (0.42) | KMT2ASLC7A5L3MBTL1 | |
| SCHEMBL13536230 | 0.88 | CTRB1 (0.51) | NPC1RAB9AKMT2ACTRB1L3MBTL1 | |
| SCHEMBL13536301 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 | |
| SCHEMBL12195833 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP1A2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409765-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3409765-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | Codexis, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2446025-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9404092-B2 | Ketoreductase-mediated stereoselective route to alpha chloroalcohols | CODEXIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160160187-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-06-09 | — | — | US | disclosed |
| EP-2069303-B1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9296992-B2 | Ketoreductase-mediated stereoselective route to alpha chloroalcohols | CODEXIS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150240217-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-08-27 | — | — | US | disclosed |
| US-9029112-B2 | Ketoreductase-mediated stereoselective route to alpha chloroalcohols | CODEXIS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140308732-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20120190086-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2446025-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | Codexis, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | NPC1 959/4885RAB9A 2076/4885CYP1A2 920/4885 |
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | NPC1 406/4885RAB9A 1820/4885CYP1A2 3784/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | NPC1 569/4885RAB9A 2012/4885CYP1A2 2459/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | NPC1 375/4885RAB9A 1786/4885CYP1A2 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.